Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Research association - 24/07/2024 Graphic in which the various thematic lines of the performance centre are shown in a circle using symbols, e.g. the health thematic line as a heart with a graph of an ECG measurement.

    SPI-MP: pioneer in personalised medical technology

    Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.

    https://biopro-v9-test-gi.xanium.io/en/article/news/spi-mp-pioneer-personalised-medical-technology
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://biopro-v9-test-gi.xanium.io/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
  • Press release - 05/07/2024

    The Symphony of Organelles

    With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/symphony-organelles
  • Press release - 03/07/2024

    CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

    CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities
  • Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024 BIOPRO_logo.jpg

    Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

    The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/customised-healthcare-all-biopro-partner-eu-project-preciseu
  • Press release - 24/06/2024

    Trustworthy AI Made in Mannheim

    How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/trustworthy-ai-made-mannheim
  • Press release - 21/06/2024

    Cyber Valley: World's first ELLIS Institute opens

    At the finale of the Cyber Valley Days, and Science Minister Petra Olschowski opened the ELLIS Institute Tübingen, heralding the next phase of the AI Innovation Campus. With the world's first ELLIS Institute, Cyber Valley is gaining further radiance. Olschowski also announced at the ceremony that the Karlsruhe Institute of Technology (KIT) is joining the Cyber Valley Community.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/cyber-valley-worlds-first-ellis-institute-opens
  • Press release - 17/06/2024

    DNA as building material for tiny machines and artificial cells

    Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/dna-building-material-tiny-machines-and-artificial-cells
  • Press release - 13/06/2024

    Eyesight from a 3D Printer

    Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/eyesight-3d-printer
  • Press release - 12/06/2024

    Pathogen identification — next-generation sequencing optimizes diagnostics

    Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/pathogen-identification-next-generation-sequencing-optimizes-diagnostics
  • Press release - 06/06/2024

    Festo Expands its Portfolio with Multilayer Manifolds

    Festo is expanding its portfolio to include multilayer manifolds made of plastic (bonded manifolds) in order to be able to offer manufacturers of medical and laboratory equipment solutions from a single source. To this end, Festo is taking over the production systems and processes for manufacturing these complex plastic manifolds from Carville, a leading company in this field.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/festo-expands-its-portfolio-multilayer-manifolds
  • Press release - 20/05/2024

    seleon GmbH becomes part of the aesco solutions group

    On May 17, 2024, aesco solutions, a leading group for production and development services (CDMO) for medical device companies, and D11Z. Ventures GmbH & Co. KG (formerly Zukunftsfonds Heilbronn) announce the closing of the acquisition of seleon GmbH.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/seleon-gmbh-becomes-part-aesco-solutions-group
  • Press release - 24/04/2024

    CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

    Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
  • Press release - 19/04/2024

    Electrified bacteria

    PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/bakterien-unter-strom
  • Press release - 18/04/2024

    Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform

    The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
  • Press release - 11/04/2024

    How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation

    Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
  • Press release - 10/04/2024

    Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program

    Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
  • Press release - 10/04/2024

    Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform

    With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
  • Press release - 27/03/2024

    Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

    Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
  • Press release - 14/03/2024

    Next milestone in the treatment of liver tumors and acute and chronic liver diseases

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
  • Press release - 13/03/2024

    Diabetes: New technology opens up improved opportunities for research

    More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/diabetes-new-technology-opens-improved-opportunities-research
  • Press release - 13/03/2024

    Protection from an unexpected source

    Contrary to common belief, not all viruses are harmful to their hosts. Sometimes viruses can even protect their hosts from infection by other viruses. Scientists at the Max-Planck-Institute for Medical Research in Heidelberg and their collaborators have now demonstrated that this is the case for so-called endogenous virophages: small DNA viruses that are mostly found inserted into the genomes of single-cell eukaryotes.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/protection-unexpected-source
  • Press release - 05/03/2024

    New Center for Synthetic Genomics

    Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-center-synthetic-genomics
  • Press release - 04/03/2024

    Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

    HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million

Page 1 / 7

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search